Hatchtech Pty.
Latest round
- Series A
Last raised
- May 2005
Total raised
- $2.2M
Investors
- 5
About Hatchtech Pty.
Hatchtech Pty. Ltd.Founded in Melbourne, Australia, Hatchtech Pty. Ltd. specializes in developing medical solutions for head lice. The company achieved FDA approval for its flagship product, Xeglyze® Lotion, in June 2020.Hatchtech Pty Ltd's primary product is Xeglyze® Lotion, a prescription pediculicide specifically designed for the topical treatment of head lice infestations in patients aged six months and older. Approved by the FDA in June 2020, Xeglyze® offers a unique lotion formulation that requires only a single 10-minute application, eliminating the need for nit combing, which is often a challenging aspect of traditional lice treatments. The active ingredient, abametapir, operates through a novel mechanism of action that inhibits metalloproteinases critical to egg development and lice survival, significantly reducing the likelihood of resistance that has been observed with other treatments containing permethrin, malathion, and pyrethrin.The revenue model for Hatchtech Pty Ltd is primarily driven by the sale of its flagship product, Xeglyze®, through a direct-to-consumer approach and partnerships with healthcare providers and pharmacies. Transactions occur on a prescription basis, with healthcare professionals facilitating the initial patient access and treatment recommendation. The company benefits from established relationships with pharmacies that stock Xeglyze®, ensuring accessibility for end-users while simultaneously managing supply chain logistics. Pricing strategies reflect the product's novel formulation and clinical efficacy, positioning it within the competitive landscape of pediatric dermatological treatments.6 mn to further develop its pipeline of products aimed at treating head lice. The company is working on expanding its market presence in North America and Europe by the end of 2023, focusing on strategic partnerships with healthcare providers to enhance distribution and accessibility. Additionally, Hatchtech aims to introduce new formulations of Xeglyze® in the coming years, addressing various treatment needs within the pediatric population.
Who invested in Hatchtech Pty.
5 investors across 1 round
See all investors in Hatchtech Pty.
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
May 30, 2005
Amount
$2.2M
Investors
Questions about Hatchtech Pty.
Who invested in Hatchtech Pty.?
Hatchtech Pty. has 5 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Hatchtech Pty. raised?
Hatchtech Pty. has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Hatchtech Pty. last raise money?
Hatchtech Pty.'s most recent round on record is a Series A, in May 2005.
What does Hatchtech Pty. do?
Hatchtech Pty. is a pharmaceuticals company.
Where is Hatchtech Pty. headquartered?
Hatchtech Pty. is headquartered in Melbourne, Australia.
Which VCs invest in companies like Hatchtech Pty.?
Among active investors with capital left to deploy, Blackbird, AirTree Ventures, Square Peg and Immutable Ventures back pharmaceuticals companies at Hatchtech Pty.'s stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like Hatchtech Pty.? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.